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Abstract
Background: Among young people up to 18 years of age, approximately 5 % have attention deficit hyperactivity
disorder (ADHD), many of whom have symptoms persisting into adulthood. ADHD is associated with increased
risk of co-morbid psychiatric disorders, including substance misuse. Many will be prescribed medication, namely
methylphenidate, atomoxetine, dexamphetamine and lisdexamfetamine. If so, it is important to know if interactions
exist and if they are potentially toxic.
Methods: Three databases (Medline, EMBASE and PsychINFO) from a 22 year period (1992 – June 2014) were
searched systematically. Key search terms included alcohol, substance related disorders, methylphenidate,
atomoxetine, dexamphetamine, lisdexamfetamine, and death, which identified 493 citations (344 after removal
of duplicates). The eligibility of each study was assessed jointly by two investigators, leaving 20 relevant articles.
Results: We identified only a minimal increase in side-effects when ADHD medication (therapeutic doses) was
taken with alcohol. None of the reviewed studies showed severe sequelae among those who had overdosed on
ADHD medication and other coingestants, including alcohol.
Conclusions: The numbers across all the papers studied remain too low to exclude uncommon effects. Also,
studies of combined effects with novel psychoactive substances have not yet appeared in the literature.
Nevertheless, no serious sequelae were identified from combining ADHD medication with alcohol/illicit
substances from the pre-novel psychoactive substance era.
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Background
Among young people up to 18 years of age, approxi-
mately 5 % world-wide are said to have attention deficit
hyperactivity disorder (ADHD), a neurodevelopmental
syndrome of impulsiveness, inattention, and overactivity
that can result in long-term educational and social dis-
advantage [1, 2]. Symptoms persist into adulthood for a
significant minority [3]. Co-morbid substance use disor-
ders (SUD) involving alcohol and cannabis misuse but
also stimulants, depressants, hallucinogens and now
novel psychoactive substances (NPS) or ‘legal highs’
emerge in adolescence [4]. Young people with ADHD
are significantly more likely to develop SUDs than those
without ADHD [5].
Many people with ADHD are prescribed medication
for their symptoms, particularly stimulants, (often me-
thylphenidate and dexamphetamine) and atomoxetine
(NICE 2006). If an individual is suspected of misusing
substances, it is crucial to understand if it safe also to
prescribe medication. We contacted the manufacturers
who recommended that stimulants and atomoxetine not
be coingested with alcohol or illicit substances. They
had no specific information on potential interactions.
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There is limited empirical evidence to guide whether it
is advised to treat ADHD before, simultaneously, or only
after remission of SUDs [6, 7]. Current guidelines sug-
gest that cannabis use may not be a contraindication to
pharmacological treatment but due to shared neuro-
chemical mechanisms, and while not explicitly men-
tioned, certain novel psychoactive substances (NPAs),
‘cocaine is likely to be a real hazard’ [8]. In the absence
of such information, faced with adolescents misusing
substances the tendency is for clinicians to avoid pre-
scribing. As adolescents with untreated compared to
treated ADHD may have poorer long-term outcomes,
this may leave the most vulnerable without adequate
intervention [9].
Methylphenidate and dexamphetamine are sympatho-
mimetic agents thought to act both in the central ner-
vous system (CNS) and peripherally by enhancing
dopaminergic and noradrenergic transmission through
blockade of relevant transporters [10]. There is theoret-
ical potential and some animal evidence for additive
effects between prescribed and non-prescribed sym-
pathomimetic agents [11, 12] potentially resulting in a
toxic sympathomimetic syndrome with prominent car-
diac and neurological effects [10, 12]. Such a syndrome
may underly so-called ‘excited delirium’; agitation, para-
noia, hyperthermia and muscle breakdown, symptoms
similar to neuroleptic malignant syndrome [13]. How-
ever, there is also evidence that different stimulants may
compete for receptor binding sites limiting the potential
for additive effects [14].
Atomoxetine is a selective noradrenaline reuptake in-
hibitor metabolised by the hepatic oxidase system [15].
It has a chemical structure that resembles the SSRI flu-
oxetine, that has been implicated in the emergence of
mania or the serotonin syndrome, comprised of mental,
autonomic and neurological effects [16]. This suggests
that toxic or tolerability effects could arise in alcohol
misusing individuals [17], through additive effects with
stimulants or with NPS that impact serotonin receptors.
Methods
We systematically searched three databases (Medline,
EMBASE and PsychINFO) from the past 22-years
(1992 – June 2014) using PRISMA guidelines [18]. Only
those articles that had abstracts available in the English
language were included. We used the key search terms
alcohol, substance related disorders, death, and com-
bined these with methylphenidate, atomoxetine, dex-
amphetamine and lisdexamfetamine in turn.
Titles and abstracts of all articles found were screened
by XB and PM. Full text articles were screened by XB
and PM. The references of all full text articles included
were also hand searched to identify any other potentially
relevant articles. Study quality was assessed using the
relevant tools from Critical Appraisal Skills Program
(CASP) or the STROBE document as appropriate to the
study type [19].
We included articles which mentioned the coingestion
of ADHD medication (methylphenidate, dexampheta-
mine, lisdexamfetamine and atomoxetine) with another
substance including alcohol, publications relating to ani-
mal models, and, due to the paucity of data regarding
adolescents, all age groups. Also, to clarify mechanisms
that might underlie toxicity, we included certain articles
covering the physiological effects of ADHD medication
alone. We excluded articles relating to the abuse of
ADHD medication alone, case reports, articles relating
to exposure of illicit drugs or alcohol in utero, foetal al-
cohol syndrome, and to cigarette smokers only.
Our main outcome was to identify any potential effects
(whether positive or negative) on an individual should
they combine their ADHD medication with alcohol or an
illicit substance. We acknowledge the dangers of diversion
of stimulant medication in the substance misuse popula-
tion; however our study did not focus on this element.
Results
The search strategy identified 493 citations (344 after re-
moval of duplicates), of which 59 were potentially
relevant. We also obtained 6 other articles from hand
searching the references, providing 65 articles (Fig. 1).
Twenty articles met inclusion criteria. In relation to bias,
six of the included studies were found to have a low risk
of bias [20–25], four a high risk [26–29] and 10 an un-
sure risk of bias [17, 30–38].
Discussion
Methylphenidate and alcohol
There was one animal study of methylphenidate and
alcohol [31] and four of the combination in humans
[28, 29, 34, 36]. The animal study reported that me-
thylphenidate reduced the consumption of ethanol by
mice and when simultaneously injected, ethanol and
methylphenidate interact to increase locomotor stimu-
lation and ataxia [31].
One human study was laboratory based and suggested
that when delivered experimentally by mouth, the com-
bination was well tolerated without serious adverse ef-
fects [34]. Two studies of users reported that alcohol
ingestion often preceded that of methylphenidate and,
interspersed with methylphenidate, continued over re-
peated administrations [28, 29]. Participants reported
consuming significantly more alcohol when used in con-
junction with methylphenidate relative to when they
used alcohol alone. Combined methylphenidate-alcohol
use was described as producing euphoria, energy and a
diminished sense of drunkenness. Some likened the ex-
perience to using alcohol with cocaine. A final human
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study combined data from randomized controlled trials
of methylphenidate treatment of ADHD among sub-
stance users. This reported that adolescents with higher
baseline use of ethanol were more likely to have gastro-
intestinal symptoms (not further defined) relative to pla-
cebo [36]. However there was no significant difference
in serious adverse events between treatment groups.
They found no increase in the diversion of methylphen-
idate in the substance misuse versus the placebo group.
Methylphenidate with other drugs
Two trials of methylphenidate among users of other am-
phetamine and cocaine [35, 39] and one experimental
toxicology study reported no serious adverse effects
[36]. However, cocaine users taking methylphenidate
reported loss of the positive subjective effects of co-
caine and more sadness, euphoria and insomnia. A
meta-regression [25] and an RCT [40] reported that as
a treatment for ADHD, methylphenidate was ineffective
in the presence of SUD.
Two accident and emergency toxicology studies re-
ported no additional toxicity when methylphenidate was
combined with other agents [27, 32]. A randomized
cross-over placebo controlled trial reported that, in the
main, the combination of methylphenidate produced
MDMA type effects but increased blood pressure to a
greater degree than either alone [14].
Dexamfetamine
Two studies examined combinations of dexamfetamine
with alcohol [22, 38]. As with methylphenidate, partici-
pants reported that using dexamphetamine made it
possible to ‘drink like a trooper’ while socializing for
longer, with less perceived drunkenness or loss of con-
trol than with alcohol alone.
Atomoxetine
Two studies explored combinations of atomoxetine and
alcohol [17, 21]. Nausea was more likely in heavy
drinkers taking atomoxetine, however there were no
other differences in treatment emergent side effects.
Conclusions
As diagnoses of ADHD have increased among young
people of substance using age, the problem of prescrib-
ing for substance users with ADHD has become a
Fig. 1 Flow chart of systematic review and study selection
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common dilemma [31]. This review explores current
available information concerning risks of toxicity at-
tached to pharmacological treatment of ADHD in the
context of substance misuse.
On the basis of experimental studies, and studies of al-
cohol dependent individuals, when methylphenidate,
dexamphetamine or atomoxetine are ingested orally with
alcohol, acute severe side-effects appear uncommon.
However, as co-ingestion of stimulants such as methyl-
phenidate or amphetamine with alcohol may enable
more ‘late night partying’ and high levels of alcohol con-
sumption, there is enhanced risk of more chronic harm
from alcohol toxic effects [29, 31]. We did not identify
serious adverse side-effects in those with poly-drug mis-
use using ADHD medication, even in overdose.
Despite the theoretical possibility of serotonergic,
hyperdopaminergic or other hyper stimulated states, on
the basis of limited evidence, apart from one study sug-
gesting hypertension following a combination of methyl-
phenidate and MDMA, ADHD medication does not
normally add to toxicity of alcohol or illicit substances
from the pre-novel psychoactive substance (NPS) era.
Limitations include the relatively small numbers in the
studies cited. In part, this may reflect a fundamental
problem with the science highlighted by Bauman [41];
banning psychoactive agents seriously impedes research
into the effects of substances in widespread use alone
and in combination by large numbers of young people.
In addition, there is no data concerning combinations of
cannabis and ADHD medications. However, as cannabis
is ubiquitous in the substance using community, it is
likely that many adolescents prescribed medications are
also using cannabis apparently without acute mishap.
However, we lack data concerning any longer term prob-
lems with this practice. The effect of combining ADHD
medication and NPS is unknown and the numbers in
published studies are too few to exclude unusual reac-
tions. ADHD medication appears less effective or even
ineffective among those with SUD and if nevertheless
prescribed, its use, efficacy and combination with other
substances should be closely monitored in an appropri-
ately cautioned consumer.
With appropriate caution, including explanations of
the limits of the science, it appears that a blanket contra-
indication is not justified when considering treatment of
ADHD in selected substance users.
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